Hiring?
Logo

Synthetic haemoglobin

location_on

France

Short Summary

Synthetic haemoglobin is a breakthrough technology in both the biotech (aerobic cell agriculture) and medtech (treatment of anoxia, stroke, infarction, pulmonary insufficiency, arteriopathy of the limbs, etc.) fields.

Overview

Target
A$720,000
Minimum
A$14,000
Investment Raised
N/A
Previous Rounds N/A
Stage Pre-Startup/R&D
Investor Role Any

Highlights

  • Medtech risks are reduced by Biotech applications
  • The market for both areas is global
  • We have a patent (USA, Canada, Europe, China, South Korea, Australia)
  • It is a disruptive technology
Please note: Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. This platform is targeted solely at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. This information has not been approved as a financial promotion, and you must carry out your own due diligence before making an investment decision.

Ask a question

Got a question about this project?

Sign up to view the full pitch

It's free to discover the next big thing

Already have an account?

Similar Projects

Global Pro
30% raised

Lifelancer

location_on South East, United Kingdom

Lifelancer is building a SaaS-based Freelance & Remote Job Platform in Life Science, IT & Digital Health; $5bn+ global market; Team size 10+; 45+ yrs team experience; MVP launched (www.lifelancer.net); Grants + Investment (£150K+); SEIS + EIS

• Addressing the unmet need in fast growing $5 billion global market
• High growth international SaaS business, COVID proof, remote & cloud-based

A$870,000

Target

A$8,700

Min per Investor

Executive
0% raised

Longevity Clinic 48%-98%

location_on Geneva, Switzerland

Biomedicine Longevity Clinic Offering an innovative well-aging method focused to generate tailored programs aiming at improving the biological age. A team of specialists operating in aspects like biochemistry and telomerase.

• Quick financial recoup
• Investment A: Associate 100'000.- / 48% ROI buy and sell agreement
• Investment B: Corporate Bond 50'000.- ...

A$14,000,000

Target

A$72,000

Min per Investor

Global Pro
61% raised

CanCertain

location_on North West, United Kingdom

CanCertain enables optimal drug treatment based on a patient’s own cancer cells as opposed to current practice which relies heavily on indicative biomarkers and generic tests. CanCertain utilises protected 21st-century 3D Cell cultures technology.

• Revenue Generating Oncology Startup!
• Protected 3D Cell culture based Precision Oncology Test!
• EIS Eligible investment opportunity at an at...

A$1,000,000

Target

A$43,000

Min per Investor